SARS-CoV-2-specific CD4 T cell Longevity Correlates with Th17-like Phenotype

Overview

Journal iScience

Publisher Cell Press

Date 2022 Aug 22

PMID 35992306

Authors

Kazutaka Terahara

Takashi Sato

Yu Adachi

Keisuke Tonouchi

Taishi Onodera

Saya Moriyama

Lin Sun

Tomohiro Takano

Ayae Nishiyama

Ai Kawana-Tachikawa

Tetsuro Matano

Takayuki Matsumura

Masaharu Shinkai

Masanori Isogawa

Yoshimasa Takahashi

Affiliations

Soon will be listed here.

Abstract

Determinants of memory T cell longevity following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain unknown. In addition, phenotypes associated with memory T cell longevity, antibody titers, and disease severity are incompletely understood. Here, we longitudinally analyzed SARS-CoV-2-specific T cell and antibody responses of a unique cohort with similar numbers of mild, moderate, and severe coronavirus disease 2019 cases. The half-lives of CD4 and CD8 T cells were longer than those of antibody titers and showed no clear correlation with disease severity. When CD4 T cells were divided into Th1-, Th2-, Th17-, and Tfh-like subsets, the Th17-like subset showed a longer half-life than other subsets, indicating that Th17-like cells are most closely correlated with T cell longevity. In contrast, Th2- and Tfh-like T cells were more closely correlated with antibody titers than other subsets. These results suggest that distinct CD4 T cell subsets are associated with longevity and antibody responses.

Citing Articles

Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.

Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.

PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.

Remodeling of the chromatin landscape in peripheral blood cells in patients with severe Delta COVID-19.

Akimov V, Tychinin D, Antonova O, Shaymardanov A, Voronina M, Deinichenko K Front Immunol. 2024; 15:1415317.

PMID: 39712003 PMC: 11662282. DOI: 10.3389/fimmu.2024.1415317.

Early acquisition of S-specific Tfh clonotypes after SARS-CoV-2 vaccination is associated with the longevity of anti-S antibodies.

Lu X, Hayashi H, Ishikawa E, Takeuchi Y, Dychiao J, Nakagami H Elife. 2024; 12.

PMID: 38716629 PMC: 11078543. DOI: 10.7554/eLife.89999.

Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case-Control Study.

Domenech-Montoliu S, Puig-Barbera J, Pac-Sa M, Orrico-Sanchez A, Gomez-Lanas L, Sala-Trull D Epidemiologia (Basel). 2024; 5(2):167-186.

PMID: 38651389 PMC: 11036210. DOI: 10.3390/epidemiologia5020012.

Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study.

Hogan A, Wu S, Toor J, Olivera Mesa D, Doohan P, Watson O PLoS Med. 2023; 20(11):e1004195.

PMID: 38016000 PMC: 10715640. DOI: 10.1371/journal.pmed.1004195.

References

Saris A, Reijnders T, Reijm M, Hollander J, de Buck K, Schuurman A . Enrichment of CCR6 CD8 T cells and CCL20 in the lungs of mechanically ventilated patients with COVID-19. Eur J Immunol. 2021; 51(6):1535-1538. PMC: 8250259. DOI: 10.1002/eji.202049046. View

Long Q, Jia Y, Wang X, Deng H, Cao X, Yuan J . Immune memory in convalescent patients with asymptomatic or mild COVID-19. Cell Discov. 2021; 7(1):18. PMC: 7993859. DOI: 10.1038/s41421-021-00250-9. View

Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845-848. DOI: 10.1038/s41591-020-0897-1. View

Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C . Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N Engl J Med. 2021; 386(5):492-494. PMC: 8823651. DOI: 10.1056/NEJMc2119358. View

Mathew D, Giles J, Baxter A, Oldridge D, Greenplate A, Wu J . Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020; 369(6508). PMC: 7402624. DOI: 10.1126/science.abc8511. View

Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F . SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020; 587(7833):270-274. DOI: 10.1038/s41586-020-2598-9. View

Bert N, Clapham H, Tan A, Chia W, Tham C, Lim J . Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med. 2021; 218(5). PMC: 7927662. DOI: 10.1084/jem.20202617. View

Singh S, Zhang H, Foley J, Hedrick M, Farber J . Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol. 2007; 180(1):214-21. DOI: 10.4049/jimmunol.180.1.214. View

Kasatskaya S, Ladell K, Egorov E, Miners K, Davydov A, Metsger M . Functionally specialized human CD4 T-cell subsets express physicochemically distinct TCRs. Elife. 2020; 9. PMC: 7773335. DOI: 10.7554/eLife.57063. View

10.

Poon M, Rybkina K, Kato Y, Kubota M, Matsumoto R, Bloom N . SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci Immunol. 2021; 6(65):eabl9105. PMC: 8626868. DOI: 10.1126/sciimmunol.abl9105. View

11.

Wheatley A, Juno J, Wang J, Selva K, Reynaldi A, Tan H . Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021; 12(1):1162. PMC: 7896046. DOI: 10.1038/s41467-021-21444-5. View

12.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

13.

Juno J, Tan H, Lee W, Reynaldi A, Kelly H, Wragg K . Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26(9):1428-1434. DOI: 10.1038/s41591-020-0995-0. View

14.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

15.

Ohnishi K, Sakaguchi M, Kaji T, Akagawa K, Taniyama T, Kasai M . Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn J Infect Dis. 2005; 58(2):88-94. View

16.

Geginat J, Sallusto F, Lanzavecchia A . Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med. 2001; 194(12):1711-9. PMC: 2193568. DOI: 10.1084/jem.194.12.1711. View

17.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

18.

Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland M, Davies D, Johnston R . Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity. 2008; 28(6):847-58. PMC: 2504733. DOI: 10.1016/j.immuni.2008.04.018. View

19.

Tang F, Quan Y, Xin Z, Wrammert J, Ma M, Lv H . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011; 186(12):7264-8. DOI: 10.4049/jimmunol.0903490. View

20.

DuPage M, Bluestone J . Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol. 2016; 16(3):149-63. DOI: 10.1038/nri.2015.18. View